ASSESSMENT OF THE EFFECTIVENESS OF COMBINED ANTI-HYPERTENSION TREATMENT IN HYPERTENSION WITH OBESITY. ASSESSMENT OF THE EFFECTIVENESS OF COMBINED ANTI-HYPERTENSION TREATMENT IN HYPERTENSION WITH OBESITY
Keywords:
arterial hypertension, obesity, antihypertensive drugs, hypertensive disease, comorbiditiy, combination therapyAbstract
Despite the ongoing advancements in modern medicine, hypertension remains one of the most pressing issues among cardiovascular diseases. Currently, the incidence of hypertension among the global population is rapidly increasing. The rapid growth of this disease leads to an increase in disability worldwide, as well as an increase in overall mortality. To date, hypertension has not occurred independently, but a number of various pathological processes have been identified, including obesity, diabetes mellitus, coronary heart disease, and kidney dysfunction. Among patients with hypertension combined with obesity and other comorbidities, type 2 diabetes mellitus and hyperlipidemia were more common (53% and 83%, respectively). Several studies have shown that arterial hypertension plays a very important role in the development of carotid artery stenosis (45%), coronary heart disease (43%), and left ventricular hypertrophy (40%) [1]. Based on the results of the aforementioned analysis, timely treatment of GK using drugs with a wide range of effects allows for a sharp reduction in future risk factors and an improvement in the quality of life of patients. In recent years, a number of scientific studies have focused on studying the effectiveness of combined drugs in the absence of monotherapy in patients with hypertension and obesity.
References
Romano, S., Idolazzi, C., Fava, C. et al. Prevalence and Comorbidities of Resistant Hypertension: A Collaborative Population-Based Observational Study. High Blood Press Cardiovasc Prev 25, 295–301 (2018).
Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cífková R, Dominiczak AF, Grassi G, Jordan J, Poulter NR, Rodgers A, Whelton PK. Gipertenziya. Nat Rev Dis Primerlari. 2018; 4 :18014.
Oliva RV, Bakris GL. Keksa odamlarda gipertenziyani davolash. J Gerontol Biol Sci Med Sci. 2012; 67 :1343–51.
Pimenta E, Oparil S. Gipertenziyani boshqarishda qat'iy kombinatsiyalar: bemorning istiqbollari va olmesartan-amlodipin kombinatsiyasining rivojlanishi va foydasi uchun mantiqiy asoslar. Vasc sog'liq uchun xavf boshqaruvchisi. 2008; 4 :653–64.
Burnier M. Antihipertenziv kombinatsiyalangan davolash: zamonaviy holat. Curr Hypertens Rep. 2015; 17:51 .
Rubio-Guerra AF, Kastro-Serna D, Elizalde-Barrera CI, Ramos-Brizuela LM. Gipertenziyani davolash uchun kombinatsiyalangan terapiyaning hozirgi tushunchalari: kombinatsiyalangan kaltsiy kanal blokerlari va RAAS inhibitörleri. Integr qon bosimi nazorati. 2009; 2 :55–62.
Mensah GA, Bakris G. Kattalardagi yuqori qon bosimini davolash va nazorat qilish Cardiol Clin. 2010;28:609–22
Kerni, Bosh vazir; Uelton, M.; Reynolds, K.; Muntner, P.; Uelton, PK; U, J. Gipertenziyaning global yuki: butun dunyo bo'ylab ma'lumotlarni tahlil qilish. Lancet 2005 , 365 , 217–223.
GBD 2015 Semizlik bo'yicha hamkorlar. 25 yil davomida 195 mamlakatda ortiqcha vazn va semirishning sog'liqqa ta'siri . N Engl J Med . 2017; 377 ( 1 ):13-27.
Wormser D, Kaptoge S, Di Angelantonio E va boshqalar. Tana massasi indeksi va qorin bo'shlig'idagi yog'lilikning yurak-qon tomir kasalliklari bilan alohida va birlashtirilgan assotsiatsiyasi: 58 ta istiqbolli tadqiqotlarni birgalikda tahlil qilish . Lancet . 2011; 377 ( 9771 ):1085-1095.
Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Tana massasi indeksi va oxirgi bosqichdagi buyrak kasalligi xavfi . Enn Intern Med . 2006; 144 ( 1 ):21-28.
Loef M, Walach H. O'rta yoshdagi semirish va demans: Qo'shma Shtatlar va Xitoyda demans tarqalishining meta-tahlili va tuzatilgan prognozi . Semirib ketish . 2013 yil; 21 ( 1 ):E51-E55.
Lauby-Secretan B, Scoccianti C, Loomis D va boshqalar. Tana yog'i va saraton - IARC ishchi guruhining nuqtai nazari . N Engl J Med . 2016; 375 ( 8 ):794-798.
Рахимова М.Э., Юлбарисов А.А., Туракулов Р.И. Особенности течения ишемической болезни сердца с метаболическим синдромом и дисфункцией почек / Терапевтический вестник Узбекистана № 3, 2021г. С 42
Appel LJ Ortiqcha vazn, semirish va gipertenziyada vaznni kamaytirish - UpToDate. 2021. [(2022-yil 18-iyunda kirish mumkin)]. Onlaynda mavjud:
Neeland IJ, Gupta S., Ayers CR, Turer AT, Rame JE, Das SR, Berry JD, Khera A., McGuire DK, Vega GL va boshqalar. Mintaqaviy yog 'tarqalishining chap qorincha tuzilishi va funktsiyasi bilan bog'liqligi. Circ. Kardiovask. Tasvirlash. 2013 yil; 6 :800–807. doi: 10.1161/CIRCIMAGING.113.000532
Shams E., Kamalumpundi V., Peterson J., Gismondi RA, Oigman V., de Gusmão Correia ML Semirib ketish bilan bog'liq gipertenziya mexanizmlari va davolashning diqqatga sazovor joylari. J. Xum. Gipertenziya. 2022; 36 :785–793. doi: 10.1038/s41371-021-00644-y
Robertson KD DNK metilatsiyasi va inson kasalligi. Nat. Rev. Genet. 2005; 6 :597–610. doi: 10.1038/nrg1655
JB Koen Semizlikdagi gipertenziya va vazn yo'qotishning ta'siri Curr Cardiol Rep , 19 ( 2017 ) , p. 98
CM Bryson , Psaty BMMDPBM Gipertenziya terapiyasida periferik alfa-1 antagonistlarining salbiy ta'sirini ko'rib chiqish Curr Contr Trials Cardiovasc Med , 3 ( 2002 ) , p. 7
